Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
University of California, Los Angeles · NCT06668922
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 72
- US sites recruiting
- 1
- Study start
- November 28, 2024
- Record last updated
- August 12, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The study will investigate the relationship between fecal bile acids, short-chain fatty acids (SCFAs), and the gut microbiota in irritable bowel syndrome (IBS). The central hypothesis of this study is that specific shifts in the GI microbiome composition correlate with altered colonic SCFAs and BAs and contribute to IBS symptoms. Primary aims include: (a) identifying GI microbiome signatures in IBS subtypes (IBS-C and IBS-D) and matched controls, and test if microbiome signatures in these groups correlate with fecal SCFAs and bacterial fermentation of an indigestible carbohydrate (inulin) after a dietary challenge (fecal inulin), and (b) determining if GI microbiome signatures in IBS subtypes and controls correlate with fecal BAs or markers of SCFA production (fecal SCFAs or inulin) and test if BAs correlate with fecal SCFAs or inulin.
The target population is adults ages 18-65 years meeting Rome IV criteria for IBS (both diarrhea- and constipation-predominant, IBS-D and IBS-C) and asymptomatic controls. Primary outcomes will be fecal bile acid excretion and profile, short-chain fatty acid excretion and profile, colonic transit, and fecal microbiota. Secondary outcomes will be stool characteristics based on responses to validated bowel diaries. Stool samples will be collected from participants during the last 2 days of a 4-day 100 g fat diet and split into 3 samples for fecal microbiota, SCFA, and bile acid analysis.
Being studied: Inulin
Conditions: Irritable Bowel Syndrome (IBS)
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 18-75
- Individuals with irritable bowel syndrome (IBS)
- Healthy volunteers (healthy controls) with no prior history of gastrointestinal (GI) disease or symptoms
- No dietary restrictions other than vegetarian
Exclusion Criteria
- Inflammatory bowel disease, celiac disease, or certain types of abdominal cancer, as well as those with thyroid or liver issues
- Abdominal surgery or abdominal radiation within 6 months of study participation, with an exception for C-section or gallbladder removal
- Use of any prescription, over the counter, or herbal medications known to affect gastrointestinal function or study interpretation, such as opioids, inflammatory drugs or certain antidepressants, within 6 months prior to study participation for healthy volunteers, or within 2 days of study participation for participants with IBS.
- An exception will be permitted for limited use of stable low doses of antidepressants for individuals who have been taking them for a period greater than one month.
- Rescue medication such as Bisacodyl (dulcolax) to relieve severe constipation and allow for stool collection will be permitted when needed.
- Use of Ozempic and Ozempic-type medications
- Pregnant or breastfeeding women
- Antibiotic use within 3 months of study participation
- Use of prebiotics or probiotics within the 2 weeks before the study initiation
- Regular tobacco use within the past 6 months
Recruiting US locations
University of California, Los Angeles
Los Angeles, CA 90095
Site contact: Ren Cutrer · (310) 794-9507 · rcutrer@mednet.ucla.edu
Similar studies in California
All nutrition & metabolism studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1/Phase 2
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Regeneron Pharmaceuticals
- Location
- Los Angeles, CA + 4 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteersPhase 1
The Effects of Dietary Supplementation on Serum Protein Glycosylation
University of California, Davis
- Location
- Sacramento, CA
- Eligibility basics
- Ages 18–45
- RecruitingHealthy volunteersPhase 1
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
University of California, San Diego
- Location
- San Diego, CA
- Eligibility basics
- Ages 60+